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BSTRACT
nder the auspices of the American College of Cardiology
oundation (ACCF) and the American Society of Nuclear
ardiology (ASNC), an appropriateness review was conducted
or radionuclide cardiovascular imaging (RNI), specifically
ated single-photon emission computed tomography myocar-
ial perfusion imaging (SPECT MPI). The review assessed
he risks and benefits of the imaging test for several indications
r clinical scenarios and scored them based on a scale of 1 to 9,
here the upper range (7 to 9) implies that the test is generally
cceptable and is a reasonable approach, and the lower range (1
o 3) implies that the test is generally not acceptable and is not
reasonable approach. The mid range (4 to 6) implies that the
est may be generally acceptable and may be a reasonable
pproach for the indication. The indications for this review
ere primarily drawn from existing clinical practice guidelines
nd modified based on discussion by the ACCF Appropriate-
ess Criteria Working Group and the Technical Panel mem-
ers who rated the indications. The method for this review was
ased on the RAND/UCLA approach for evaluating appro-
riateness, which blends scientific evidence and practice expe-
ience. A modified Delphi technique was used to obtain first-
nd second-round ratings of 52 clinical indications. The
atings were done by a Technical Panel with diverse member-
hip, including nuclear cardiologists, referring physicians (in-
luding an echocardiographer), health services researchers, andpayer (chief medical officer). These results are expected to
ave a significant impact on physician decision making and
erformance, reimbursement policy, and future research direc-
ions. Periodic assessment and updating of criteria will be
ndertaken as needed.
REFACE
his report is the first in a series of technical documents that
ritically and systematically document, review, and categorize
ppropriateness criteria of cardiovascular diagnostic tests and
rocedures utilized by cardiologists in their everyday clinical
ractice. Both the ACCF and ASNC believe that a careful
lending of evidence-based information and clinical experience
an help guide a more efficient and equitable allocation of
ealth care resources. The ultimate objective of these reviews is
o improve patient care and health outcomes in a cost-effective
anner, without constraining the crucial role of physician
udgment in the face of diverse clinical presentations and
arying patient characteristics.
The appropriateness criteria in this report serve as a guide
or the responsible use of SPECT MPI and related re-
ources. Our approach is not to diminish the acknowledged
ncertainty of clinical decision making by statistical means
r consensus techniques, but to recognize that real differ-
nces in clinical opinion are grounds for more research and
or even more careful deliberation of each indication and
atient. Also, not doing a study that is deemed appropriate
ay be a correct decision in light of unique patient and
linical information.
This document would not have been possible without the
edicated effort of the Technical Panel, comprising 12
xperts in cardiovascular care, some with special background
n nuclear cardiology and others with impeccable credentials
n general cardiovascular medicine, echocardiography, and
ealth services cardiovascular research. This diversity made
or a wide range of scoring for each indication. It is much
asier to “game” or “bias” the scoring process by limiting
anel membership solely to specialists of the particular
rocedure being evaluated for appropriateness. Such special-
sts would have a natural tendency to rate each indication
igher than would nonspecialists of a given test or proce-
ure. Thus, it would appear to be more grounded and
esponsible to have a professional group with a wider range
f skills and insights to balance the deliberations, as re-
ected in the background of the Technical Panel shown in
ppendix C.
Special mention and thanks are due to Peggy Chris-
iansen, Librarian, Griffith Resource Library, who assisted
n the literature search; Sue Morrisson, Associate Specialist,
ho assisted in the editing and formatting of the document;
nd Gregory Thomas, MD, FACC, who was an external
eviewer for the development of the indications used in this
ocument.
Ralph Brindis, MD, MPH, FACC
Chair, Appropriateness Criteria Working Group
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mprovements in cardiovascular imaging technology and their
pplication, coupled with increasing therapeutic options for
ardiovascular disease, have led to an increase in cardiovascular
maging. In 2002, some 9.3 million myocardial perfusion
rocedures were performed (1,2). Diagnostic imaging services
eimbursed underMedicare’s physician fee schedule grewmore
apidly than any other type of physician service from 1999 to
003 (3,4). At the same time, the armamentarium of nonin-
asive diagnostic tools expanded with innovations in new
ontrast agents, molecular radionuclide imaging, perfusion
chocardiography, computed tomography for coronary angiog-
aphy and calcium score, and magnetic resonance imaging
MRI) for myocardial structure and viability. As the field of
ardiovascular radionuclide nuclear imaging continues to ad-
ance along with other imaging modalities, the health care
ommunity needs to understand how to best incorporate these
echnologies into daily clinical care.
In an effort to respond to this need, the ACCF, in
onjunction with ASNC, undertook a process to determine the
ppropriate indications for cardiovascular RNI. The ACCF/
SNC Appropriateness Criteria for Single-Photon Emission
omputed Tomography Myocardial Perfusion Imaging
SPECT MPI) project was initiated to support the delivery of
uality cardiovascular care and to ensure the effective use of
dvanced diagnostic imaging tools. This project, which focuses
n the use of gated SPECT MPI for adults, is part of an
ngoing effort by the ACCF to rigorously examine the appro-
riateness of all established imaging modalities.
ETHODS
he method for this review was based on the RAND/
CLA approach for evaluating appropriateness, which
lends scientific evidence and practice experience (5). A
odified Delphi technique was used to obtain first- and
econd-round ratings of 52 clinical indications or scenarios
y a specially constituted Technical Panel. This 12-member
echnical Panel had diverse membership comprising nu-
lear cardiologists, referring physicians (including an echo-
ardiographer), health services researchers, and a payer
epresentative (chief medical officer) (see Appendix C).
pecialists in nuclear cardiology accounted for only 58% of
he Technical Panel membership. This diversity ensured a
alanced composition and the necessary expertise of the
anel.
The 52 indications that were rated encompass the majority
f cases seen in cardiovascular nuclear testing. All were mod-
fied based on discussion by the Appropriateness Criteria
orking Group and the Technical Panel that rated the
ndications. Although not comprehensive, the indications are
haracteristic of the average practice and were developed based
n existing clinical practice guidelines and expert opinion.
riteria were drafted for each indication to be as specific as
ossible for each patient population addressed (the develop-
ent of indications is discussed in Appendix A). As discussed
c
in Appendix B, they include aspects such as the pre-test
ikelihood of coronary artery disease (CAD) for symptomatic
atients and Framingham risk criteria to determine the risk of
oronary heart disease for asymptomatic patients (6).
The ratings assessed whether the use of SPECT MPI for
ach indication was appropriate, uncertain, or inappropriate.
n rating each indication, the Technical Panel was asked to
se the following definition of appropriateness:
An appropriate imaging study is one in which the expected
incremental information, combined with clinical judgment,
exceeds the expected negative consequences* by a sufficiently
wide margin for a specific indication that the procedure is
generally considered acceptable care and a reasonable ap-
proach for the indication.
The Technical Panel scored each indication as follows:
edian score 7 to 9: Appropriate test for that specific
indication (test is generally acceptable and is a reason-
able approach for the indication).
edian score 4 to 6: Uncertain or possibly appropriate test
for that specific indication (test may be generally accept-
able and may be a reasonable approach for the indica-
tion). (Uncertainty also implies that more research
and/or patient information is needed to classify defini-
tively the indication as appropriate and to update the
criteria.)
edian score 1 to 3: Inappropriate test for that specific
indication (test is not generally acceptable and is not a
reasonable approach for the indication).
Appendices A and B provide details about the methods
nd definitions used in this report. Discussion of the
ethodological issues involved in the development of ap-
ropriateness criteria is also found in the report entitled,
ACCF Proposed Method for Evaluating the Appropriate-
ess of Cardiovascular Imaging” (7).
ESULTS OF RATINGS
ables 1 through 9 sequentially list the 52 indications by
urpose, clinical scenario, and their ratings, as obtained
rom the second-round rating sheets. In addition, Tables 10
hrough 12 arrange the indications into three main scoring
ategories—those that were rated as inappropriate (I, me-
ian score of 1 to 3), uncertain or possibly appropriate (U,
edian score of 4 to 6), and appropriate (A, median score of
to 9), respectively.
Table 10 lists the 13 indications that were rated as
nappropriate (i.e., the imaging test is not generally accept-
ble and is not a reasonable approach for the indication).
his does not preclude, however, the performance of the
est if justifiable because of special clinical and patient
Expected negative consequences include the risks of the procedure (i.e., radiation or
ontrast exposure) and the downstream impact of poor test performance such as delay
n diagnosis (false negatives) or inappropriate diagnosis (false positives).
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ill require a documented exception from the physician.
Table 11 lists the 27 indications that were rated as
ppropriate (the imaging test is generally acceptable and
s a reasonable approach for the indication). It is recom-
ended that these indications will receive reimburse-
ent. However, appropriateness does not necessarily
mply that the test being rated is the initial clinical
pproach to be taken.
Table 12 lists the 12 indications that were rated as
ncertain (i.e., the imaging test may be generally acceptable
nd may be a reasonable approach for the indication).
dditional data and research are required before these
ndications can be rated definitively as appropriate. These
ndications should be reimbursed. The clinical community
oes not necessarily consider uncertain indications as those
hat should not be performed—many may be the standard
f care in specific regions of the U.S.
Other tables, including documentation of the mean
bsolute deviation from the median and level of agreement
or each indication, are found in the online appendix at
ww.acc.org. Unless otherwise noted, a succession of bullets Uor a specific indication implies that all are required com-
onents of that indication. Abbreviations used in the tables
nd the text of this report are listed below.
bbreviations
CS acute coronary syndromes
ABG coronary artery bypass grafting surgery
AD coronary artery disease
HD coronary heart disease
CG electrocardiogram
F heart failure
PI myocardial perfusion imaging
ETs estimated metabolic equivalents of exercise
STEMI non–ST-segment elevation myocardial infarction
CI percutaneous coronary intervention
NA radionuclide angiography
NI radionuclide cardiovascular imaging (in this report,
SPECT MPI)
PECT MPI single-photon emission computed tomography
myocardial perfusion imaging
TEMI ST-segment elevation myocardial infarction
A unstable angina
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Indication
Appropriateness
Criteria
(Median Score)
Evaluation of Chest Pain Syndrome
1. ● Low pre-test probability of CAD
● ECG interpretable AND able to exercise
I (2.0)
2. ● Low pre-test probability of CAD
● ECG uninterpretable OR unable to exercise
U* (6.5)
3. ● Intermediate pre-test probability of CAD
● ECG interpretable AND able to exercise
A (7.0)
4. ● Intermediate pre-test probability of CAD
● ECG uninterpretable OR unable to exercise
A (9.0)
5. ● High pre-test probability of CAD
● ECG interpretable AND able to exercise
A (8.0)
6. ● High pre-test probability of CAD
● ECG uninterpretable OR unable to exercise
A (9.0)
Acute Chest Pain (in Reference to Rest Perfusion Imaging)
7. ● Intermediate pre-test probability of CAD
● ECG – no ST elevation AND initial cardiac enzymes
negative
A (9.0)
8. ● High pre-test probability of CAD
● ECG – ST elevation
I (1.0)
New-Onset/Diagnosed Heart Failure With Chest Pain Syndrome
9. ● Intermediate pre-test probability of CAD A (8.0)*Median scores of 3.5 and 6.5 are rounded to the middle (Uncertain). Note: I (Inappropriate), U (Uncertain), and A
(Appropriate).Table 2. Detection of CAD: Asymptomatic (Without Chest Pain Syndrome)
Indication
Appropriateness
Criteria
(Median Score)
Asymptomatic
10. ● Low CHD risk (Framingham risk criteria) I (1.0)
11. ● Moderate CHD risk (Framingham) U (5.5)
New-Onset or Diagnosed Heart Failure or LV Systolic Dysfunction
Without Chest Pain Syndrome
12. ● Moderate CHD risk (Framingham)
● No prior CAD evaluation AND no planned cardiac catheterization
A (7.5)
Valvular Heart Disease Without Chest Pain Syndrome
13. ● Moderate CHD risk (Framingham)
● To help guide decision for invasive studies
U (5.5)
New-Onset Atrial Fibrillation
14. ● Low CHD risk (Framingham)
● Part of the evaluation
U* (3.5)
15. ● High CHD risk (Framingham)
● Part of the evaluation
A (8.0)
Ventricular Tachycardia
16. ● Moderate to high CHD risk (Framingham) A (9.0)*Median scores of 3.5 and 6.5 are rounded to the middle (Uncertain). Note: I (Inappropriate), U (Uncertain), and A
(Appropriate).
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Indication
Appropriateness
Criteria
(Median Score)
Asymptomatic
17. ● Low CHD risk (Framingham) I (1.0)
18. ● Moderate CHD risk (Framingham) U (4.0)
19. ● Moderate to high CHD risk (Framingham)
● High-risk occupation (e.g., airline pilot)
A (8.0)
20. ● High CHD risk (Framingham) A (7.5)Note: I (Inappropriate), U (Uncertain), and A (Appropriate).Table 4. Risk Assessment With Prior Test Results
Indication
Appropriateness
Criteria
(Median Score)
Asymptomatic OR Stable Symptoms
Normal Prior SPECT MPI Study
21. ● Normal initial RNI study
● High CHD risk (Framingham)
● Annual SPECT MPI study
I (3.0)
22. ● Normal initial RNI study
● High CHD risk (Framingham)
● Repeat SPECT MPI study after 2 years or greater
A (7.0)
Asymptomatic OR Stable Symptoms
Abnormal Catheterization OR Prior SPECT MPI Study
23. ● Known CAD on catheterization OR prior SPECT MPI study
in patients who have not had revascularization procedure
● Asymptomatic OR stable symptoms
● Less than 1 year to evaluate worsening disease
I (2.5)
24. ● Known CAD on catheterization OR prior SPECT MPI study
in patients who have not had revascularization procedure
● Greater than or equal to 2 years to evaluate worsening disease
A (7.5)
Worsening Symptoms
Abnormal Catheterization OR Prior SPECT MPI Study
25. ● Known CAD on catheterization OR prior SPECT MPI study A (9.0)
Asymptomatic
CT Coronary Angiography
26. ● Stenosis of unclear significance U* (6.5)
Asymptomatic
Prior Coronary Calcium Agatston Score
27. ● Agatston score greater than or equal to 400 A (7.5)
28. ● Agatston score less than 100 I (1.5)
UA/NSTEMI, STEMI, or Chest Pain Syndrome
Coronary Angiogram
29. ● Stenosis of unclear significance A (9.0)
Duke Treadmill Score
30. ● Intermediate Duke treadmill score
● Intermediate CHD risk (Framingham)
A (9.0)*Median score of 3.5 and 6.5 are rounded to the middle (Uncertain). Note: I (Inappropriate), U (Uncertain), and A
(Appropriate).
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Indication
Appropriateness
Criteria
(Median Score)
Low-Risk Surgery
31. ● Preoperative evaluation for non-cardiac surgery risk
assessment
I (1.0)
Intermediate-Risk Surgery
32. ● Minor to intermediate perioperative risk predictor
● Normal exercise tolerance (greater than or equal to
4 METS)
I (3.0)
33. ● Intermediate perioperative risk predictor OR
● Poor exercise tolerance (less than 4 METS)
A (8.0)
High-Risk Surgery
34. ● Minor perioperative risk predictor
● Normal exercise tolerance (greater than or equal to
4 METS)
U (4.0)
35. ● Minor perioperative risk predictor
● Poor exercise tolerance (less than 4 METS)
A (8.0)
36. ● Asymptomatic up to 1 year post normal catheterization,
non-invasive test, or previous revascularization
I (3.0)Note: I (Inappropriate), U (Uncertain), and A (Appropriate).Table 6. Risk Assessment: Following Acute Coronary Syndrome
Indication
Appropriateness
Criteria
(Median Score)
STEMI—Hemodynamically Stable
37. ● Thrombolytic therapy administered
● Not planning to undergo catheterization
A (8.0)
STEMI—Hemodynamically Unstable, Signs of Cardiogenic Shock,
or Mechanical Complications
38. ● Thrombolytic therapy administered I (1.0)
UA/NSTEMI—No Recurrent Ischemia or No Signs of HF
39. ● Not planning to undergo early
catheterization
A (8.5)
ACS—Asymptomatic Post Revascularization (PCI or CABG)
40. ● Routine evaluation prior to hospital
discharge
I (1.0)Note: I (Inappropriate), U (Uncertain), and A (Appropriate).
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Indication
Appropriateness
Criteria
(Median Score)
Symptomatic
41. ● Evaluation of chest pain syndrome A (8.0)
Asymptomatic
42. ● Asymptomatic prior to previous
revascularization
● Less than 5 years after CABG
U (6.0)
43. ● Symptomatic prior to previous revascularization
● Less than 5 years after CABG
U (4.5)
44. ● Asymptomatic prior to previous
revascularization
● Greater than or equal to 5 years after CABG
A (7.5)
45. ● Symptomatic prior to previous revascularization
● Greater than or equal to 5 years after CABG
A (7.5)
46. ● Asymptomatic prior to previous
revascularization
● Less than 1 year after PCI
U* (6.5)
47. ● Symptomatic prior to previous revascularization
● Less than 1 year after PCI
I (3.0)
48. ● Asymptomatic prior to previous
revascularization
● Greater than or equal to 2 years after PCI
U* (6.5)
49. ● Symptomatic prior to previous revascularization
● Greater than or equal to 2 years after PCI
U (5.5)*Median scores of 3.5 and 6.5 are rounded to the middle (Uncertain). Note: I (Inappropriate), U (Uncertain), and A
(Appropriate).Table 8. Assessment of Viability/Ischemia
Indication
Appropriateness
Criteria
(Median Score)
Ischemic Cardiomyopathy
Assessment of Viability/Ischemia (Includes SPECT Imaging
for Wall Motion and Ventricular Function)
50. ● Known CAD on catheterization
● Patient eligible for revascularization
A (8.5)Note: I (Inappropriate), U (Uncertain), and A (Appropriate).Table 9. Evaluation of Ventricular Function
Indication
Appropriateness
Criteria
(Median Score)
Evaluation of Left Ventricular Function
51. ● Non-diagnostic echocardiogram A (9.0)
Use of Potentially Cardiotoxic Therapy (e.g., Doxorubicin)
52. ● Baseline and serial measurements A (9.0)Note: I (Inappropriate), U (Uncertain), and A (Appropriate).
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Indication
Appropriateness
Criteria
(Median Score)
Detection of CAD: Symptomatic—Evaluation of Chest Pain Syndrome
1. ● Low pre-test probability of CAD
● ECG interpretable AND able to exercise
I (2.0)
Detection of CAD Symptomatic—Acute Chest Pain (in Reference to Rest Perfusion Imaging)
8. ● High pre-test probability of CAD
● ECG: ST elevation
I (1.0)
Detection of CAD: Asymptomatic (Without Chest Pain Syndrome)
10. ● Low CHD risk (Framingham risk criteria) I (1.0)
Risk Assessment: General and Specific Patient Populations—
Asymptomatic
17. ● Low CHD risk (Framingham) I (1.0)
Risk Assessment With Prior Test Results: Asymptomatic OR Stable Symptoms—
Normal Prior SPECT MPI Study
21. ● Normal initial RNI study
● High CHD risk (Framingham)
● Annual SPECT MPI study
I (3.0)
Risk Assessment With Prior Test Results: Asymptomatic OR Stable Symptoms—
Abnormal Catheterization OR Prior SPECT MPI Study
23. ● Known CAD on catheterization OR prior SPECT MPI
study in patients who have not had revascularization
procedure
● Asymptomatic OR stable symptoms
● Less than 1 year to evaluate worsening disease
I (2.5)
Risk Assessment With Prior Test Results: Asymptomatic—
Prior Coronary Calcium Agatston Score
28. ● Agatston score less than 100 I (1.5)
Risk Assessment: Preoperative Evaluation for Non-Cardiac Surgery—
Low-Risk Surgery
31. ● Preoperative evaluation for non-cardiac surgery risk
assessment
I (1.0)
Risk Assessment: Preoperative Evaluation for Non-Cardiac Surgery—
Intermediate-Risk Surgery
32. ● Minor to intermediate perioperative risk predictor
● Normal exercise tolerance (greater than or equal to 4 METS)
I (3.0)
Risk Assessment: Preoperative Evaluation for Non-Cardiac Surgery—High Risk Surgery
36. ● Asymptomatic up to 1 year post normal catheterization,
non-invasive test, or previous revascularization
I (3.0)
Risk Assessment: Following Acute Coronary Syndrome STEMI—Hemodynamically Unstable,
Signs of Cardiogenic Shock, or Mechanical Complications
38. ● Thrombolytic therapy administered I (1.0)
Risk Assessment: Following Acute Coronary Syndrome—
Asymptomatic Post-Revascularization (PCI or CABG)
40. ● Routine evaluation prior to hospital discharge I (1.0)
Risk Assessment: Post-Revascularization (PCI or CABG)—Asymptomatic
47. ● Symptomatic prior to previous revascularization
● Less than 1 year after PCI
I (3.0)Note: I (Inappropriate), U (Uncertain), and A (Appropriate).
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Indication
Appropriateness
Criteria
(Median Score)
Detection of CAD: Symptomatic—
Evaluation of Chest Pain Syndrome
3. ● Intermediate pre-test probability of CAD
● ECG interpretable AND able to exercise
A (7.0)
4. ● Intermediate pre-test probability of CAD
● ECG uninterpretable OR unable to exercise
A (9.0)
5. ● High pre-test probability of CAD
● ECG interpretable AND able to exercise
A (8.0)
6. ● High pre-test probability of CAD
● ECG uninterpretable OR unable to exercise
A (9.0)
Detection of CAD: Symptomatic—
Acute Chest Pain (in Reference to Rest Perfusion Imaging)
7. ● Intermediate pre-test probability of CAD
● ECG: no ST elevation AND initial cardiac enzymes negative
A (9.0)
Detection of CAD: Symptomatic—
New-Onset/Diagnosed Heart Failure With Chest Pain Syndrome
9. ● Intermediate pre-test probability of CAD A (8.0)
Detection of CAD: Asymptomatic—
New-Onset or Diagnosed Heart Failure or LV Systolic Dysfunction
Without Chest Pain Syndrome
12. ● Moderate CHD risk (Framingham)
● No prior CAD evaluation AND no planned cardiac
catheterization
A (7.5)
Detection of CAD: Asymptomatic (Without Chest Pain Syndrome)—
New-Onset Atrial Fibrillation
15. ● High CHD Risk (Framingham)
● Part of the evaluation
A (8.0)
Detection of CAD: Asymptomatic (Without Chest Pain Syndrome)—
Ventricular Tachycardia
16. ● Moderate to high CHD risk (Framingham) A (9.0)
Risk Assessment: General and Specific Patient Populations—
Asymptomatic
19. ● Moderate to high CHD risk (Framingham)
● High-risk occupation (e.g., airline pilot)
A (8.0)
20. ● High CHD risk (Framingham) A (7.5)
Risk Assessment With Prior Test Results: Asymptomatic OR Stable Symptoms—
Normal Prior SPECT MPI Study
22. ● Normal initial RNI study
● High CHD risk (Framingham)
● Repeat SPECT MPI study after 2 years or greater
A (7.0)
Risk Assessment With Prior Test Results: Asymptomatic OR Stable Symptoms—
Abnormal Catheterization or Prior SPECT MPI Study
24. ● Known CAD on catheterization OR prior SPECT MPI study
in patients who have not had revascularization procedure
● Greater than or equal to 2 years to evaluate worsening disease
A (7.5)
Risk Assessment With Prior Test Results: Worsening Symptoms—
Abnormal Catheterization OR Prior SPECT MPI Study
25. ● Known CAD on catheterization OR prior SPECT MPI study A (9.0)Continued on next page
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Indication
Appropriateness
Criteria
(Median Score)
Risk Assessment With Prior Test Results: Asymptomatic—
Prior Coronary Calcium Agatston Score
27. ● Agatston score greater than or equal to 400 A (7.5)
Risk Assessment With Prior Test Results: UA/NSTEMI, STEMI, or
Chest Pain Syndrome—Coronary Angiogram
29. ● Stenosis of unclear significance A (9.0)
Risk Assessment With Prior Test Results—
Duke Treadmill Score
30. ● Intermediate Duke treadmill score
● Intermediate CHD risk (Framingham)
A (9.0)
Risk Assessment: Preoperative Evaluation for Non-Cardiac Surgery—
Intermediate-Risk Surgery
33. ● Intermediate perioperative risk predictor OR
● Poor exercise tolerance (less than 4 METS)
A (8.0)
Risk Assessment: Preoperative Evaluation for Non-Cardiac Surgery—
High-Risk Surgery
35. ● Minor perioperative risk predictor AND
● Poor exercise tolerance (less than 4 METS)
A (8.0)
Risk Assessment: Following Acute Coronary Syndrome—
STEMI-Hemodynamically Stable
37. ● Thrombolytic therapy administered
● Not planning to undergo catheterization
A (8.0)
Risk Assessment: Following Acute Coronary Syndrome—
UA/NSTEMI—No Recurrent Ischemia OR No Signs of HF
39. ● Not planning to undergo early catheterization A (8.5)
Risk Assessment: Post-Revascularization (PCI or CABG)—
Symptomatic
41. ● Evaluation of chest pain syndrome A (8.0)
Risk Assessment: Post-Revascularization (PCI or CABG)—
Asymptomatic
44. ● Asymptomatic prior to previous revascularization
● Greater than or equal to 5 years after CABG
A (7.5)
45. ● Symptomatic prior to previous revascularization
● Greater than or equal to 5 years after CABG
A (7.5)
Assessment of Viability/Ischemia: Ischemic Cardiomyopathy
(Includes SPECT Imaging for Wall Motion and Ventricular Function)
50. ● Known CAD on catheterization
● Patient eligible for revascularization
A (8.5)
Evaluation of Left Ventricular Function
51. ● Non-diagnostic echocardiogram A (9.0)
Evaluation of Ventricular Function:
Use of Potentially Cardiotoxic Therapy (e.g., Doxorubicin)
52. ● Baseline and serial measurements A (9.0)Note: I (Inappropriate), U (Uncertain), and A (Appropriate).
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should be reimbursed, but additional research and/or patient information is required during
updates of the criteria in order to rate them definitively as being appropriate)
Indication
Appropriateness
Criteria
(Median Score)
Detection of CAD: Symptomatic—
Evaluation of Chest Pain Syndrome
2. ● Low pre-test probability of CAD
● ECG uninterpretable OR unable to exercise
U* (6.5)
Detection of CAD: Asymptomatic (Without Chest Pain Syndrome)
11. ● Moderate CHD risk (Framingham) U (5.5)
Detection of CAD: Asymptomatic—
Valvular Heart Disease Without Chest Pain Syndrome
13. ● Moderate CHD risk (Framingham)
● To help guide decision for invasive studies
U (5.5)
Detection of CAD: Asymptomatic (Without Chest Pain Syndrome)—
New-Onset Atrial Fibrillation
14. ● Low CHD risk (Framingham)
● Part of the evaluation
U* (3.5)
Risk Assessment: General and Specific Patient Populations—
Asymptomatic
18. ● Moderate CHD risk (Framingham) U (4.0)
Risk Assessment With Prior Test Results: Asymptomatic—
CT Coronary Angiography
26. ● Stenosis of unclear significance U* (6.5)
Risk Assessment: Preoperative Evaluation for Non-Cardiac Surgery—
High-Risk Surgery
34. ● Minor perioperative risk predictor
● Normal exercise tolerance (greater than or
equal to 4 METS)
U (4.0)
Risk Assessment: Post-Revascularization (PCI or CABG)—
Asymptomatic
42. ● Asymptomatic prior to previous
revascularization
● Less than 5 years after CABG
U (6.0)
43. ● Symptomatic prior to previous revascularization
● Less than 5 years after CABG
U (4.5)
Risk Assessment: Post-Revascularization (PCI or CABG)—
Asymptomatic
46. ● Asymptomatic prior to previous
revascularization
● Less than 1 year after PCI
U* (6.5)
48. ● Asymptomatic prior to previous
revascularization
● Greater than or equal to 2 years after PCI
U* (6.5)
49. ● Symptomatic prior to previous revascularization
● Greater than or equal to 2 years after PCI
U (5.5)*Median scores of 3.5 and 6.5 are rounded to the middle (Uncertain). Note: I (Inappropriate), U (Uncertain), and A
(Appropriate).
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he ACCF/ASNC appropriateness review of SPECTMPI
esulted in the following distribution of criteria:
Inappropriate—13 indications (25%)
Appropriate—27 indications (52%)
Uncertain—12 indications (23%)
he indications rated as appropriate were derived more
ften from existing clinical practice guidelines (89%) than
as the case for uncertain (67%) or inappropriate indica-
ions (62%). The mean absolute deviation from the median
as higher for uncertain indications (1.7), somewhat lower
or appropriate indications (1.4), and much lower for
ndications rated as inappropriate (0.7). Of the 27 indica-
ions rated as appropriate, 6 (22%) had a mean absolute
eviation from the median of 1.5 or greater (see online
ppendix). For those indications, it is clear that there was
trong disagreement among the panelists as to the final
ating of appropriateness—a median score in any of the
hree rating ranges does not necessarily imply that each
anelist endorses the final recommendation.
Indications contained in this report were constructed and
elected to cover a wide variety of common presentations and
cenarios for which a nuclear cardiology study might be
rdered. Indications vary by several factors, including risk (e.g.,
HD and preoperative risk), test results, exercise ability, and
uration since prior testing (see Appendices A and B). Factors
re specific to the condition and population being considered,
nd the different clinical information contained in each indi-
ation has been crafted to be helpful to the physician faced with
specific patient scenario. The indications do not correspond
irectly to ICD-9 codes as they convey more information than
ound in the ICD-9 classification system. However, it is
ecognized that the 52 indications that are listed are not
xhaustive of every possible use in cardiology, nor is every
ndication written with enough specificity to apply to every
atient who presents for evaluation. In addition, a rating of
ppropriate for an indication does not necessarily mean that the
se of SPECT MPI would be the first choice of testing for a
articular patient profile.
There may be medical reasons that would preclude the
pplication of the appropriateness criteria to a specific case, and
linician judgment should be used at all times in the applica-
ion of these criteria. Furthermore, the local availability or
uality of equipment or personnel may influence the selection
f appropriate imaging procedures. Appropriateness criteria, in
ther words, are not substitutes for sound clinical judgment
nd practice experience with each patient and clinical presen-
ation. For example, the rating of an indication as inappropri-
te should not preclude a provider from performing nuclear
ardiology procedures when there are patient- and condition-
pecific data to support that decision. Conversely, not doing a
tudy that is deemed appropriate may be a correct decision in
ight of unique patient and clinical information.
l
iThe primary objective of this report is to provide guid-
nce regarding the perceived suitability of SPECT MPI for
iverse clinical scenarios. Although consensus is desirable,
omplete agreement among the diverse membership of the
echnical Panel was believed to be artificial and not
ecessarily of clinical value. Two rounds of rating with
ntervening discussion, following the RAND/UCLA
ethod (5), did lead to some consensus among the panel-
sts. It was believed, however, that further attempts to
otivate consensus could artificially dilute differences in
pinion among panelists and reduce real uncertainty.
The appropriateness criteria in this report are expected to be
seful for clinicians, health care facilities, and third-party
ayers in the delivery of quality cardiovascular care. For
xample, individual clinicians could use the ratings as a sup-
ortive decision or educational tool when ordering a SPECT
PI or providing a referral to another qualified physician. The
riteria also may be used to respond to a referring physician
ho has ordered a SPECT MPI for an inappropriate indica-
ion. Facilities and payers can use the criteria either prospec-
ively in the design of protocols and pre-authorization proce-
ures or retrospectively for quality reports. It is also expected
hat appropriate indications will receive reimbursement. In
ontrast, inappropriate indications will likely require additional
ocumentation to justify payment because of unique circum-
tances or the clinical profile of the patient. An uncertain rating
mplies possible appropriateness and should not be used to
eny reimbursement.
When used for accountability, appropriateness criteria
hould be employed in conjunction with systems that
upport quality improvement. Prospective pre-authorization
rocedures, for example, may be used most effectively once
retrospective review has identified a pattern of potential
nappropriate use. Because the criteria are based on current
cientific evidence and the deliberations of the Technical
anel, they can be used to help resolve future reimbursement
ases or appeals but should not be applied to cases com-
leted before issuance of this report.
The linking of indications rated as generally acceptable
ractice with analysis of related patient outcomes, and a review
f what is “necessary” care*, will improve understanding of
egional variations in imaging and the potential for ensuring the
quitable and efficient allocation of resources for diagnostic studies.
oreover, appropriateness reviews of other noninvasive modali-
ies will make more information available to guide the selection
mong alternative tests and the assessment of their incremental
ffectiveness. Further exploration of the indications that are rated
s “uncertain” or possibly appropriate will generate new empirical
esearch and the data required to further define the appropriate-
ess of SPECT MPI. Finally, periodic assessment and updating
f indications and criteria will be required as new data and field
xperience become available.
A necessity review of appropriate indications can be done to ascertain the nature and
evel of care that is essential (i.e., is of such consequence in terms of net benefits that
t should be made available to all population groups across regions).
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anel Selection
n initial list of potential Technical Panel members was
enerated based on a Call for Nominations issued to all
elevant parties in February 2005. Panel members were
elected by the Appropriateness Criteria Working Group in
manner that ensured an appropriate balance with respect
o expertise in the specific modality, academic versus private
ractice, research, and specialty training. Specialists in
uclear cardiology were limited to 58% of panelists.
evelopment of Indications
he process for creating a first-round set of indications
nvolved outside review and careful reference to relevant
CC/AHA clinical practice guidelines. The indications
apture the major scenarios faced by nuclear cardiologists or
eferring physicians, but they are not meant to be inclusive
f all potential indications for which a SPECT MPI study
ight be performed. Review was done by the ACCF/
SNC Appropriateness Criteria Working Group, includ-
ng additional comments from an external reviewer in the
eld of nuclear cardiology. As a result of the meeting of the
echnical Panel before the second-round of rating, the
ndications were clarified and modified. A final set of 52
ndications comprised the list of possible clinical scenarios
hat were rated for appropriateness by the panelists and
ompiled for this report.
ssumptions
ll indications were considered with the following impor-
ant assumptions:
. Panel members were to assume that all techniques with
specifically different radiopharmaceuticals and imaging
protocols were available for each indication, and that
each was performed in a manner similar to that found in
the published literature.
. Unless otherwise noted, all indications referred to gated
SPECT MPI. All radionuclide perfusion imaging indi-
cations also assume gated SPECT MPI determination
of global ventricular function (i.e., left ventricular ejec-
tion fraction) and regional wall motion as part of the
evaluation.
. For all stress imaging, the mode of stress testing was
assumed to be exercise for patients able to exercise. For
patients unable to exercise, pharmacologic stress testing
was assumed to be used. Further background on the
rationale for the assumption of exercise testing is avail-
able in the ACC/AHA 2002 Guideline Update for
Exercise Testing (8).
ating Process
he Technical Panel was instructed to follow the RAND/
CLA appropriateness method, including a modified Delphi
rocess involving two rounds of ratings, which included a tace-to-face meeting (5). The appropriateness method com-
ines expert clinical judgment with the scientific literature in
valuating the benefits and risks of medical procedures. Ratings
f the net benefits and risks of performing medical procedures
or a comprehensive array of potential patient indications or
cenarios are obtained from a multidisciplinary panel of expert
linicians. Each panel member has equal weight in producing
he final result, and the method does not force consensus. The
AND Web site (http://www.rand.org/publications/MR/
R1269/index.html) provides details of the RAND/UCLA
ethod (5).
The first round of ratings was completed individually
ith no interaction among panel members. The panel was
hen convened for a face-to-face meeting that was facilitated
y a moderator. The goal of the meeting was to focus
iscussion on indications for which the first-round scores of
he panel were widely divergent and to allow all views to be
eard. The second-round ratings were conducted individu-
lly subsequent to the face-to-face meeting. The second-
ound ratings were used to determine the final appropriate-
ess score based on the median score for each indication.
A measure of the level of disagreement was applied to each
core. This project employed the BIOMEDConcerted Action
n Appropriateness definition for a panel size of 11 to 13
embers. As defined in the RAND/UCLA manual (5), the
IOMED rule for agreement () is that no more than three
anelists rate the indication outside the 3-point region con-
aining the median; for disagreement (), at least four panelists
ate in each extreme rating region (i.e., 1 to 3 and 7 to 9).
easures of agreement and the dispersion of ratings (mean
bsolute deviation from the median) may highlight areas where
efinitions are not clear or ratings are inconsistent, where
anelist perceptions of the “average” patient might differ, or
here various specialty groups or individual panelists may have
ifferences of clinical opinion. The measures are not meant to
orce consensus but to achieve better understanding of the
esults.
At the face-to-face meeting, each panelist received a per-
onalized rating form that indicated his or her rating for each
ndication and the distribution of ratings of other members of
he panel, but without personal identification. In addition, the
oderator received a summary rating form with similar infor-
ation (including panelist identification), along with other
tatistics that measured the level of agreement among panel
embers. This additional information helped to identify pan-
lists who rated very differently from the rest of the panel.
hese additional measures or statistics were not shared with
anelists.
In cases of obvious disagreement or outlier scores, the
ndication was highlighted in a summary table and identifica-
ion of the outlier raters brought to the attention of the
oderator. This information was used by the moderator to
uide the panel’s discussion.
Because the Technical Panel for this appropriateness review
ad 12 members, the median score is the arithmetic mean of
he two middle most ratings. As a result, median scores such as
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October 18, 2005:1587–605 ACCF/ASNC Appropriateness Criteria: SPECT MPI.5 and 6.5 can result, which are just outside the range of the
ating scale for inappropriate and appropriate, respectively. In
his report, the 3.5 and 6.5 median scores were rounded to the
iddle or the uncertain scale: 4 to 6. This is a conservative
pproach that recognizes that inadequate scientific knowledge,
r need for further clarification of the indication, possibly
recludes assignment of the indication as appropriate or
nappropriate. The general tendency to assign a 6.5 score to an
ppropriate range or a 3.5 score to the inappropriate range was
eemed secondary to the caution necessary in protecting the
est interests of the patient. In addition, the RAND/UCLA
ethod requires that any score with disagreement be denoted
s “uncertain” (5).
Panel members were asked to incorporate scientific evidence
n their ratings, including relevant clinical practice guideline
ecommendations. All indications were evaluated based on the
vailable medical literature and the prevailing practice for the
verage physician in the average clinical setting. Where avail-
ble, both the guideline class of recommendation and level of
vidence for a specific clinical indication were presented in the
ating tables.
As set out in the RAND/UCLA Appropriateness Method
ser’s Manual (5), costs were not explicitly considered in the
atings. Panelists, however, implicitly assessed a wide constel-
ation of factors in their ratings, including patient expectations,
ost reimbursement options, and the nature and level of clinical
apacity. In the future, costs may be considered explicitly in
ubsequent stages of review and analysis, after the initial appro-
riateness review is completed. A review of the ratings that are
n the uncertain range can help to guide the development of
ew empirical research required to expand the evidence base
or future ratings. Finally, publication of the criteria merits
iscussion about how to evaluate the impact of the appropri-
teness criteria on health care practice and reimbursement
olicy.
elationships With Industry
he ACCF and its partnering organizations rigorously avoid
ny actual, perceived, or potential conflicts of interest that
ight arise as a result of an outside relationship or personal
nterest of a member of the Working Group and Technical
anel. Specifically, all members are asked to provide disclosure
tatements of all relationships that might be perceived as real or
otential conflicts of interest. These statements were reviewed
y the ACCF Quality Strategic Directions Committee, dis-
ussed with all members at each meeting, and updated and
eviewed as changes occur. A table of disclosures by each
ember of the ACCF/ASNC Appropriateness Criteria
orking Group and Technical Panel can be found in Appen-
ix C.
iterature Review
echnical Panel members were asked to review relevant guide-
ines and literature when completing their ratings. Each mem-
er was provided with access to the relevant ACC/AHA
linical practice guidelines along with an updated literature mearch for relevant studies since the publication of the ACC/
HA/ASNC 2003 Guideline Update for the Clinical Use of
ardiac Radionuclide Imaging (9). A medical librarian and a
ardiovascular fellow conducted independent literature
earches, and they then compared the retrieved references to
roduce a comprehensive literature search. In addition, a
pecial table was provided to the raters that documented the
pecific section and wording of the clinical practice guidelines
elevant to the indications. Readers interested in further un-
erstanding the evidence base and rationale related to the use
f SPECT MPI are encouraged to read the guidelines listed
elow. A copy of the annotated literature search and the table
f correspondence between indications and clinical guideline
ecommendations that were provided to the Technical Panel
re available in the online appendix at www.acc.org. The
ollowing ACC/AHA guidelines were referenced in this ap-
ropriateness review:
CC/AHA/ASNC Guidelines for the Clinical Use of
Cardiac Radionuclide Imaging (9)
CC/AHA 2002 Guideline Update for Exercise Test-
ing (8)
CC/AHA 2005 Guideline Update for the Diagnosis and
Management of Chronic Heart Failure in the Adult
(10)
CC/AHA 2002 Guideline Update for Perioperative Car-
diovascular Evaluation for Noncardiac Surgery (11)
CC/AHA Guidelines for the Management of Patients
With ST-Elevation Myocardial Infarction (12)
CC/AHA 2002 Guideline Update for Management of
Patients With Chronic Stable Angina (13)
CC/AHA 2002 Guideline Update for Management of
Patients With Unstable Angina and Non–ST-Segment
Elevation Myocardial Infarction (14)
CC/AHA Practice Guidelines for Management of Pa-
tients With Valvular Heart Disease (15)
PPENDIX B: Definitions and Processes for
etermining Likelihood of Disease and Risk
etermining Pre-Test Probability of
oronary Artery Disease
hest pain syndrome. This is any constellation of symp-
oms that the physician believes may represent a complaint
onsistent with obstructive CAD. Examples of such symp-
oms include, but are not exclusive to, chest pain, chest
ightness, burning, dyspnea, shoulder pain, and jaw pain.
re-test probability of coronary artery disease (CAD). Once
he physician determines the presence of symptoms that
ay represent obstructive CAD (chest pain syndrome
resent), then the pre-test probability of CAD should be
etermined.
Although several methods exist for determining pre-test
robability of CAD (6,16), the method assumed for this
eport is a modification of a literature review (17) recom-
ended by the ACC/AHA 2002 Guideline Update for
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ate for Management of Patients With Chronic Stable
ngina (13). The reader should refer to the definitions of
ngina and Table B1.
ngina. As defined by the ACC/AHA 2002 Guideline
pdate on Exercise Testing (8):
Typical angina (definite): 1) Substernal chest pain or
discomfort that is 2) provoked by exertion or emotional
stress and 3) relieved by rest and/or nitroglycerin.
Atypical angina (probable): Chest pain or discomfort
that lacks one of the characteristics of definite or typical
angina.
Non-anginal chest pain: Chest pain or discomfort that
meets one or none of the typical angina characteristics.
etermining Pre-Test Risk Assessment
or Risk Stratification
isk assessment. The rating sheets on risk assessment
nclude indications in patients with suspected CAD.
It is assumed that clinicians will use radionuclide studies
n addition to standard methods of risk assessment as
resented in the AHA/ACC Scientific Statement: Assess-
ent of Cardiovascular Risk by Use of Multiple-Risk-
actor Assessment Equations (18). Numerous discussions
f the Framingham risk score calculation can be found
nline, including at the NHLBI Web site (http://www.
hlbi.nih.gov/about/framingham/riskabs.htm).
oronary heart disease (CHD) risk.*
CHD risk—low. Defined by the age-specific risk level
that is below average. In general, low risk will correlate
with a 10-year absolute CHD risk less than 10%.
CHD risk—moderate. Defined by the age-specific risk
level that is average or above average. In general, mod-
erate risk will correlate with a 10-year absolute CHD risk
between 10% to 20%.
No data exist for patients less than 30 or greater than 69 years, but it can be assumed
hat prevalence of CAD increases with age. In a few cases, patients with ages at the
able B1. Pre-Test Probability of CAD by Age, Gender, and Sy
Age
(yrs) Gender
Typical/Definite
Angina Pectoris
0–39 Men Intermediate
Women Intermediate
0–49 Men High
Women Intermediate
0–59 Men High
Women Intermediate
0–59 Men High
Women High
igh: Greater than 90% pre-test probability; Intermediate: Between 10% and 90%
% pre-test probability.
eproduced with permission from ACC/AHA 2002 Guideline Update for Exercisextremes of the decades listed may have probabilities slightly outside the high or low
ange.
†
cCHD risk— high. Defined as the presence of diabetes
mellitus or the 10-year absolute CHD risk of greater
than 20%.
valuating Perioperative Risk for Non-Cardiac Surgery
ethod for determining perioperative risk. Perioperative
isk was determined for this report using a “Stepwise
pproach to Preoperative Cardiac Assessment,” found in
CC/AHA 2002 Guideline Update for Perioperative Car-
iovascular Evaluation for Noncardiac Surgery (11). Based
n that algorithm, once it is determined that the patient
oes not require urgent surgery, and that there has not been
evascularization within the last five years, the clinician
hould determine the patient’s perioperative risk predictors
see the definitions in the following text). If major risk
redictors are present, coronary angiography and the post-
onement or cancellation of non-cardiac surgery should be
onsidered. Once perioperative risk predictors are assessed
ased on the algorithm, then the surgical risk and patient’s
unctional status should be used to establish the need for
oninvasive testing.
erioperative risk predictors.†
Major risk predictors. Unstable coronary syndromes,
decompensated heart failure (HF), significant arrhyth-
mias, and severe valve disease.
Intermediate risk predictors. Mild angina, prior myo-
cardial infarction (MI), compensated or prior HF, dia-
betes, or renal insufficiency.
Minor risk predictors. Advanced age, abnormal electro-
cardiogram (ECG), rhythm other than sinus, low func-
tional capacity, history of cardiovascular accident (CVA),
and uncontrolled hypertension.
urgical risk categories.†
High-risk surgery—cardiac death or MI greater than 5%.
Emergent major operations (particularly in the elderly), aortic
ms
ypical/Probable
ngina Pectoris
Nonanginal
Chest Pain Asymptomatic
Intermediate Low Very low
Very low Very low Very low
Intermediate Intermediate Low
Low Very low Very low
Intermediate Intermediate Low
Intermediate Low Very low
Intermediate Intermediate Low
Intermediate Intermediate Low
t probability; Low: Between 5% and 10% pre-test probability; Very Low: Less than
g (8).mpto
At
A
pre-tesAs defined by the ACC/AHA 2002 Guideline Update for Perioperative Cardiovas-
ular Evaluation for Noncardiac Surgery (10).
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associated with large fluid shifts and/or blood loss.
Intermediate-risk surgery— cardiac death or MI 1%
to 5%. Carotid endarterectomy, head and neck surgery,
surgery of the chest or abdomen, orthopedic surgery,
prostate surgery.
Low-risk surgery— cardiac death or MI less than 1%.
Endoscopic procedures, superficial procedures, cataract
surgery, breast surgery.
CG—Uninterpretable
his refers to ECGs with resting ST-segment depression
greater than or equal to 0.10 mV), complete left bundle-
ranch block, pre-excitation (Wolf-Parkinson-White Syn-
rome), or paced rhythm.
PPENDIX C: ACCF Appropriateness Criteria Working
roup and Technical Panel
articipants
CCF Appropriateness Criteria Working Group
alph G. Brindis, MD, MPH, FACC, Chair and Techni-
cal Panel Moderator—Regional Senior Advisor for Car-
diovascular Diseases, Oakland Kaiser Medical Center
and Clinical Professor of Medicine, University of Cal-
ifornia at San Francisco, CA
amela S. Douglas, MD, FACC, FAHA—President,
ACC and Ursula Geller Professor of Research in
Cardiovascular Disease, Duke University Medical Cen-
ter, Durham, NC
obert C. Hendel, MD, FACC, FAHA—Co-Moderator
of the Technical Panel—Midwest Heart Specialists, Fox
River Grove, IL
ric D. Peterson, MD, FACC, FAHA—Associate Profes-
sor of Medicine and Director, Cardiovascular Out-
comes, Duke University Medical Center, Durham, NC
ichael J. Wolk, MD, FACC—Immediate Past Presi-
dent, ACC and Clinical Professor of Medicine, Weill
Medical College of Cornell University, New York,
NY
oseph M. Allen, MA—Director, Clinical Decision Sup-
port, American College of Cardiology, Bethesda, MD
anesh R. Patel, MD—Fellow in Training, Duke Univer-
sity Medical Center, Durham, NCra E. Raskin, PhD—Senior Specialist, Appropriateness
Criteria, American College of Cardiology, Bethesda, MD
echnical Panel
imothy M. Bateman, MD, FACC, FAHA—Co-Director
of Cardiovascular Radiology, and Associate Professor of
Medicine, Cardiovascular Consultants, Kansas City,
MO
anuel D. Cerqueira, MD, FACC, FAHA—Chairman,
Department of Molecular and Functional Imaging and
Professor of Medicine and Radiology, Cleveland Clinic
Foundation, Cleveland, OH
aymond J. Gibbons, MD, FACC, FAHA—Professor of
Medicine and Co-Director, Nuclear Cardiology Lab,
Mayo Clinic, Rochester, MN
inda D. Gillam, MD, FACC, FAHA—Director, Echo-
cardiography Lab and Associate Professor of Medicine,
Hartford Hospital, Hartford, CT
ohn A. Gillespie, MD, FACC—Chief Medical Officer,
Blue Cross Blue Shield of Western New York, Buffalo,
NY
obert C. Hendel, MD, FACC, FAHA—Co-Moderator
of the Technical Panel – Midwest Heart Specialists, Fox
River Grove, IL
mi E. Iskandrian, MD, FACC, FAHA—Distinguished
Professor of Medicine and Radiology Section Chief,
Nuclear Cardiology Division CV Diseases, University of
Alabama at Birmingham, Birmingham, AL
cott D. Jerome, DO, FACC—Co-Director, Cardiac Im-
aging, Midatlantic Cardiovascular Association, West-
minister, MD
arlan M. Krumholz, MD, FACC, FAHA—Professor of
Medicine, Epidemiology and Public Health, Yale Uni-
versity School of Medicine, New Haven, CT
oseph V. Messer, MD, FACC, FAHA—Associates in
Cardiology and Rush University Medical Center, Glen-
coe, IL
ohn A. Spertus, MD, FACC, FAHA—Director, Out-
comes Research, Mid America Heart Institute of St.
Luke’s Hospital, Kansas City, MO
tephen A. Stowers, MD, FACC —Interventional Cardi-
ologist, Southpoint Cardiology Associates, Jacksonville,
FL
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in alphabetical order)
Committee Member Research Grant
Speakers Bureau/
Honoraria/
Expert Witness
Stock
Ownership
Board of
Directors
Consultant/
Advisory Board/
Steering
Committee
ACCF/ASNC Appropriateness Criteria Working Group
oseph M. Allen None None None None None
r. Ralph G. Brindis None None None None None
r. Pamela Douglas None None None None ● GE Healthcare
r. Robert C. Hendel ● Astellas Healthcare
● GE Healthcare
● Corantus Genetics
● Bristol-Myers-Squibb ● CV Therapeutics
r. Manesh R. Patel None None None None None
r. Eric D. Peterson ● Millennium Pharmaceuticals
● Schering Plough
● BMS/Sanofi
None None None None
ra E. Raskin None None None None None
r. Michael J. Wolk None None None None None
ACCF/ASNC Appropriateness Criteria Technical Panel
r. Timothy M. Bateman ● Bracco
● Siemens
● Astellas
● Mallinckrodt
● GE/Amsterdam
● Bristol-Myers-Squibb ● Astellar
r. Manuel D. Cerqueira ● GE Healthcare
● CV Therapeutics
● Siemens
● GE Healthcare
● CV Therapeutics
● Fujisawa
● CV Therapeutics
r. Raymond J. Gibbons ● Radiant Medical
● Innercool Therapies
● Boston Scientific
● Boehringer Ingelheim
● Spectranetics
● KAI Pharmaceuticals
● TargeGen
None None None ● CV Therapeutics
● Hawaii Biotech
● Cardiovascular
Clinical Studies
● Ther Ox
● Consumers
Union
r. Linda D. Gillam None None None None None
r. John A. Gillespie None None None None None
r. Ami E. Iskandrian ● CV Therapeutics
● Fujisawa
● GE Healthcare
● Bristol-Myers-Squibb
None None None ● CV Therapeutics
● BARIZD
r. Scott D. Jerome None None None None None
r. Harlan M. Krumholz None None None None None
r. Joseph V. Messer None None None None None
r. John A. Spertus ● CV Therapeutics
● Amgen
None None None ● CV Therapeutics
● Amgen
World Health
● CV Outcomes
● Outcomes
● Instruments
● Health
Outcomes
Sciencesr. Stephen A. Stowers ● CV Therapeutics Fujisawa None None None
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